ALPHAMAB ONCOLO.DL-000002 Capital Reinvestment Ratio

Latest as of December 2024: 0.10x

ALPHAMAB ONCOLO.DL-000002 capital reinvestment ratio. ALPHAMAB ONCOLO.DL-000002 (3NK) has a Capital Reinvestment Ratio of 0.10x as of December 2024, meaning it reinvests 0% of its operating cash flow (€212.34 Million) in capital expenditures (€21.77 Million). Check 3NK total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.

Capital Reinvestment Ratio

0.10x

Capex / Operating Cash Flow

Operating Cash Flow

€212.34 Million

EUR

Capital Expenditures

€21.77 Million

EUR

Data as of

Dec 2024

Most recent filing

Capital Reinvestment Ratio of ALPHAMAB ONCOLO.DL-000002 (2024–2024)

Capital reinvestment ratio of ALPHAMAB ONCOLO.DL-000002 from 2024 to 2024. This chart tracks ALPHAMAB ONCOLO.DL-000002's Capital Reinvestment Ratio across 1 annual periods. Also explore ALPHAMAB ONCOLO.DL-000002 net asset momentum to track the company's year-over-year net asset growth rate.

ALPHAMAB ONCOLO.DL-000002 Capital Reinvestment Ratio by Year (2024–2024)

ALPHAMAB ONCOLO.DL-000002 capital reinvestment ratio by year from 2024 to 2024. For the full cash flow conversion analysis, see cash efficiency ratio of ALPHAMAB ONCOLO.DL-000002.

Year	Reinvestment Ratio	Operating CF (EUR)	Capital Expenditures	YoY Change
2024	0.10x	€212.34 Million	€21.77 Million	—

Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow